Neurophenotype Predicts CD Disease Progression — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Neurophenotype Predicts CD Disease Progression — Stella

Home/Radiomics/

View on ClinicalTrials.gov

Recruiting

Back to Radiomics trials

Trial locations(1 site)

China

XploreMET v3.0 system, Shanghai

Key details

Sponsor

First Affiliated Hospital, Sun Yat-Sen University

Enrollment target

~500 participants

Started

May 2021

Primary completion

June 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 45 Years

Last updated June 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.